Plaque Psoriasis. Plaque psoriasis
Conditions
Interventions
Intervention 1: Intervention group: The patients use 1gr of topical Frankincense based cream on the skin lesion twice a day for a period of four weeks (28 days). Measure of topical medication is Finge
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Diagnosed with clinical of mild to moderate Plaque Psoriasis Age between 18-70 years old PASI score <12 Involvement of body surface area <10% Written informed consent
Exclusion criteria
Exclusion criteria: Gguttate, erythrodernic, psoriatic arthritis or pustular psoriasis at the time of screening; psoriasis vulgaris patients with face involvement only; Known allergic or hypersensitive reactions to cream components; Using medications that could trigger psoriasis like beta blockers, antimalarials, terbinafine, calcium channel blockers, interleukins and lithium; Previous treatment with systemic corticosteroids, biologic and immunosuppression drugs or psoralen ultraviolet A therapy within the previous four weeks; Previous treatment with local corticosteroids within the previous two weeks; Presence of skin infections or malignancy in the treatment area; Severe psoriasis; Patients who require systemically acting medications for the treatment of psoriasis; Pregnant or breast-feeding females;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Psoriasis Area Severity Index (PASI);. Timepoint: PASI score is evaluated at baseline, day 14 and day 28;. Method of measurement: Fotofinder device;. | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician Global Assessment (PGA score);. Timepoint: Outcoms are evaluated at baseline, day 14 and day 28;. Method of measurement: Physician's observation;.;The body surface area (BSA);. Timepoint: Outcoms are evaluated at baseline, day 14 and day 28;. Method of measurement: Palm method (patient's handprint);.;Assess pruritus intensity;. Timepoint: Outcoms are evaluated at baseline, day 14 and day 28;. Method of measurement: The VAS (visual analoge scale) is used. It is a criterion 10 grades are used and the patient shows the quality in quantitative form with the number;.;The DLQI (dermatology life and quality index) of the psoriasis patients;. Timepoint: Outcoms are evaluated at baseline, day 14 and day 28;. Method of measurement: Questionnaire;.;Photo of Plaque Psoriasis. Timepoint: Outcoms are evaluated at baseline, day 14 and day 28;. Method of measurement: Camera;.;Patient's satisfaction;. Timepoint: Outcoms are evaluated at day 14 and day 28;. Method of measurement: The VAS (visual analoge scale) is used. It is a criterion 10 grades are used and the patient shows the quality in quantitative form with the number;.;Adverse events of the drug;. Timepoint: Outcoms are evaluated at day 14 and day 28;. Method of measurement: Questionnaire;. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFateme Fadaei
Tehran University of Medical Sciences
Outcome results
None listed